The drug, intended to treat schizophrenia and bipolar disorder, is a generic version of London-based AstraZeneca’s Seroquel tablets.
Intellipharmaceuticals can launch its generic version of Seroquel Nov. 1, as decided by a 2012 settlement between the Toronto-based drugmaker and AstraZeneca.
Once they hit the market, the quetiapine fumarate tablets could affect AstraZeneca’s stake in the epilepsy drug market. Seroquel earned about $1.2 billion in U.S. sales for the 12 months ending in August 2016, according to Symphony Health Solutions.
More articles on supply chain:
Southwest Airlines to haul international cargo next year
Dana-Farber, Brigham and Women’s in ‘urgent need’ of platelet donations
Alnylam halts drug’s development after patient deaths in study
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
